Unknown

Dataset Information

0

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.


ABSTRACT: Programmed death-ligand 1 (PD-L1) expression is regarded as a predictive marker for anti-PD-1/PD-L1 therapy. The purpose of study was to explore the changes in PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) during treatment. Paired HNSCC tissues prior to and after cisplatin-based treatment were evaluated to determine PD-L1 protein expression by immunohistochemistry. Among the 35 HNSCC patient samples, PD-L1 expression status changed after treatment in 37.1% (13/35) of samples. Among the 13 patients whose baseline PD-L1 was negative, PD-L1 expression was increased in 9 cases (69.2%) and remained negative in 4 cases (30.8%, P = 0.003). Patients exposed to cisplatin generally showed PD-L1 up-regulation (83.3%, P = 0.037) compared to those not exposed to cisplatin (57.1%, P = 0.072). To validate these findings in vitro, changes in PD-L1 expression in HNSCC cell lines (Detroit-562, PCI-13, SNU-1041, SNU-1066, SNU-1076, and FaDu) were analyzed by western blotting and flow cytometry after treatment with cisplatin and interferon-gamma. In HNSCC cell lines, PD-L1 expression was significantly up-regulated after cisplatin, along with phosphor-MAPK/ERK kinase up-regulation. In conclusion, PD-L1 expression in HNSCC may be altered during cisplatin treatment, activating the MAPK/ERK kinase pathway.

SUBMITTER: Ock CY 

PROVIDER: S-EPMC5716702 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.

Ock Chan-Young CY   Kim Sehui S   Keam Bhumsuk B   Kim Soyeon S   Ahn Yong-Oon YO   Chung Eun-Jae EJ   Kim Jin-Ho JH   Kim Tae Min TM   Kwon Seong Keun SK   Jeon Yoon Kyung YK   Jung Kyeong Chun KC   Kim Dong-Wan DW   Wu Hong-Gyun HG   Sung Myung-Whun MW   Heo Dae Seog DS  

Oncotarget 20170616 58


Programmed death-ligand 1 (PD-L1) expression is regarded as a predictive marker for anti-PD-1/PD-L1 therapy. The purpose of study was to explore the changes in PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) during treatment. Paired HNSCC tissues prior to and after cisplatin-based treatment were evaluated to determine PD-L1 protein expression by immunohistochemistry. Among the 35 HNSCC patient samples, PD-L1 expression status changed after treatment in 37.1% (13/35) of samples.  ...[more]

Similar Datasets

| S-EPMC7226044 | biostudies-literature
| S-EPMC8058384 | biostudies-literature
| S-EPMC7156784 | biostudies-literature
| S-EPMC5055695 | biostudies-literature
2022-03-01 | PXD001438 | Pride
| S-EPMC7456462 | biostudies-literature
| S-EPMC6926111 | biostudies-literature
| S-EPMC5527359 | biostudies-literature
| S-EPMC6058339 | biostudies-literature
| S-EPMC6718257 | biostudies-literature